Annual report pursuant to Section 13 and 15(d)

Consolidated Statements of Cash Flows

v3.23.1
Consolidated Statements of Cash Flows - USD ($)
$ in Thousands
12 Months Ended
Dec. 31, 2022
Dec. 31, 2021
Cash Flows From Operating Activities    
Net loss $ (21,958) $ (14,943)
Adjustments to reconcile net loss to net cash used in operating activities:    
Depreciation and amortization 2,560 5,374
Interest accretion expense 158 496
Bad debt recovery (140)
Goodwill impairment 8,433
Intangible asset impairment 3,964
Amortization of deferred financing fees 60 122
Interest - note payable 120
Note payable fees 312
Stock-based compensation 1,258 1,255
ESPP expense 46 113
Change in fair value of note payable 1,223 (58)
Deferred income taxes (93) 38
Change in fair value of contingent consideration (223) (338)
Other gains and expenses, net (71) 61
Other changes in operating assets and liabilities:    
Accounts receivable (133) 2,148
Other current assets (216) 28
Other long-term assets 34 (118)
Accounts payable (735) (1,817)
Accrued salaries and bonus (1,421) (137)
Accrued liabilities (749) (1,086)
Long-term liabilities 171 (149)
Net cash used in operating activities (7,692) (8,719)
Cash Flows From Investing Activity    
Proceeds from sale of Interpace Pharma Solutions, net 6,528
Purchase of property and equipment (322) (354)
Sale of property and equipment 39
Net cash provided by (used in) investing activities 6,206 (315)
Cash Flows From Financing Activities    
Issuance of common stock, net of expenses 108 335
Loan proceeds - related parties 7,500
Loan proceeds - BroadOak 8,000
Loan expenses - BroadOak (312)
Payment of related party note and related interest (7,924)
Financing fees - related party (123)
Proceeds from convertible debt issuance 2,000
Borrowings on line of credit 1,000 1,500
Cash paid for repurchase of restricted shares (108)
Net cash provided by financing activities 3,000 8,976
Net increase (decrease) in cash, cash equivalents and restricted cash 1,514 (58)
Cash, cash equivalents and restricted cash from continuing operations– beginning 2,922 1,236
Cash, cash equivalents and restricted cash from discontinued operations– beginning 392 2,136
Cash, cash equivalents and restricted cash – beginning 3,314 3,372
Cash, cash equivalents and restricted cash from continuing operations– ending 4,828 2,922
Cash, cash equivalents and restricted cash from discontinued operations– ending 392
Cash, cash equivalents and restricted cash – ending $ 4,828 $ 3,314